GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Total Tax Payable

Estrella Immunopharma (Estrella Immunopharma) Total Tax Payable : $0.05 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Total Tax Payable?

Estrella Immunopharma's Total Tax Payable for the quarter that ended in Mar. 2024 was $0.05 Mil.

Estrella Immunopharma's quarterly Total Tax Payable increased from Sep. 2023 ($0.04 Mil) to Dec. 2023 ($0.05 Mil) but then stayed the same from Dec. 2023 ($0.05 Mil) to Mar. 2024 ($0.05 Mil).


Estrella Immunopharma Total Tax Payable Historical Data

The historical data trend for Estrella Immunopharma's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Total Tax Payable Chart

Estrella Immunopharma Annual Data
Trend Jun21
Total Tax Payable
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.04 0.05 0.05

Estrella Immunopharma Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Estrella Immunopharma Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines